TheEdgeResearch
Home / Stocks / HNGZY

Hangzhou Tigermed Consulting Co., Ltd (HNGZY)

OTC Healthcare Biotechnology
$4.45 ▲ +0.00%
Market Cap
$6.86B
Sector
Healthcare
Industry
Biotechnology
Beta
0.41
52-Wk Range
4-4.45
CEO
Xiao Chun Cao
Country
CN
Currency
USD

Hangzhou Tigermed Consulting Co., Ltd operates in the Biotechnology industry of the Healthcare sector, headquartered in Hangzhou, ZH, CN. The stock last traded at $4.45, up 0.00% on the session, giving a market capitalisation of $6.86B. On trailing twelve-month figures it carries a trailing P/E of 60.34, a net margin of 10.9%. Its beta of 0.41 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
60.34
Price / Sales
5.60
Price / Book
2.10
EV / EBITDA
24.50
Gross margin
26.6%
Operating margin
18.0%
Net margin
10.9%
Return on equity
Debt / equity
0.08
Current ratio
2.30
Dividend yield
0.2%
Payout ratio
43.0%
Company profile
Exchange
Other OTC
Employees
11,130
IPO date
2022-07-11
Headquarters
Hangzhou, ZH, CN
About Hangzhou Tigermed Consulting Co., Ltd

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.

Comparable companies

Hangzhou Tigermed Consulting Co., Ltd is most often compared with the following Healthcare names:

QUCYRVTYSHPMYWUXAYWUXIF
More research on HNGZY
HNGZY technical analysis HNGZY TheEdge Score Compare against peers
Open full interactive analysis & DCF →